HR001124S0032_Attachment_G_Risk_Register.xlsx

This document is an example Risk Register associated with the Broad-Spectrum Antagonists For Editors (B-SAFE) federal grant opportunity (Solicitation Number: HR001124S0032). The Risk Register identifies various risks related to the program, including the risk statement, likelihood of occurrence, potential consequence/impact, risk categorization (high, moderate, low), and mitigation strategies.

The associated federal grant opportunity is a solicitation from the Defense Advanced Research Projects Agency (DARPA) seeking innovative proposals to identify and optimize novel molecules that exhibit inhibitory effects on CRISPR-CRISPR associated proteins gene editing processes. The program is interested in transformative approaches to discover or design novel inhibitors with enhanced activity, utility, and breadth of coverage. Incremental improvements to the existing state-of-the-art are excluded. The funding instruments include Cooperative Agreements and Procurement Contracts, and the target applicant types are broadly defined as "Other". This opportunity falls under DARPA's Research and Technology Development program (CFDA 12.910).